Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity Against Influenza Infection, Safety, Tolerability, and Pharmacokinetics of CC-42344 Via a Human Viral Challenge Model in Healthy Participants

Next Previous
Trial Profile

Randomised, Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity Against Influenza Infection, Safety, Tolerability, and Pharmacokinetics of CC-42344 Via a Human Viral Challenge Model in Healthy Participants

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CC 42344 (Primary)
  • Indications Influenza A virus infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Cocrystal Pharma Inc

Most Recent Events

  • 31 Dec 2024 According to a Cocrystal Pharma Inc media release, company is working with the clinical research organization to prepare a protocol amendment for approval by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) in order to extend enrollment in this study, and to ensure necessary infection rates among enrolled study subjects.
  • 31 Dec 2024 According to a Cocrystal Pharma Inc media release, announces plans to extend enrollment in the Phase 2a human challenge study CDI-42344 due to unexpectedly low influenza infection among study participants who were challenged with a H3N2 viral strain.
  • 31 Oct 2024 According to a Cocrystal Pharma Inc media release, top-line results expected by the end of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top